Dr. Reddy's Laboratories has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).
The Nitrostat (Nitroglycerin) sublingual tablet brand had U.S. sales of around $108 Million MAT for the most recent twelve months ending in March 2016.
Dr. Reddy's Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6mg is available in bottle count size of 100.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
